Aurobindo Pharma, the fourth largest Indian pharma company with net sales above Rs.12,000 crore plus, has posted strong growth in bottom line during the second quarter ended September 2015. Its consolidated net profit went up by 21.5 per cent to Rs.452 crore from Rs.372 crore in the same period of last year. EBIDTA also improved by 18.5 per cent to Rs.787 crore from Rs.665 crore. Its consolidated net sales increased by 14.6 per cent to Rs.3,280 crore from Rs.2,862 crore. With healthy improvement in profits, EPS increased to Rs.7.74 from Rs.6.39 in the last period. The Board has approved the interim dividend of 60 per cent.
Its formulation sales increased by 20 per cent to Rs.2,681 crore from Rs.2,237 crore and contributed 79.5 per cent of its net sales. Its formulation sales in the US increased by 26 per cent to Rs.1,478 crore from Rs.1,174 crore, though its sales in Europe remained stagnant at Rs.764 crore. The formulation sales in RoW increased by 7 per cent to Rs.168 crore from Rs.157 crore. The sales of ARV increased sharply by 95 per cent to Rs.270.8 crore from Rs.138.9 crore. API sales improved only by one per cent to Rs.691 crore from Rs.685 crore and API sales contributed 20.5 per cent of gross sales.
The company generated 87 per cent of its sales through exports while domestic market contributed 13 per cent of the total. Its export sales stood at Rs.2,943 crore and domestic sales at Rs.428 crore. It received approval for 13 ANDAs during the quarter under review. Cumulative filings reached at 382 ANDAs and 200 DMFs.
N Govindarajan, managing director said, “We had a healthy YoY performance during the quarter contributed by most of our business verticals. We expect to sustain the performance with the continuation of approvals and also by further strengthening our product portfolio thorough complex products and differentiated technology.”
For the first half ended September 2015, Aurobindo's consolidated net sales increased by 13.7 per cent to Rs.6,544 crore from Rs.5,757 crore in the similar period of last year. Its net profit went up by 12.2 per cent to Rs.884 crore from Rs.788 crore. EPS surged to Rs.15.15 from Rs.13.51 in the last period. Its formulations sales improved by 18 per cent to Rs.5,318 crore from Rs.4,512 crore and API sales by 4 per cent to Rs.1,414 crore from Rs.1,355 crore. The US sales of formulation went up by 27 per cent to Rs.2,907 crore from Rs.2,290 crore and that in Europe declined to Rs.1,506 crore from Rs.1,565 crore. RoW sales of formulations moved up by 15 per cent to Rs.339 crore from Rs.295 crore.